跳至主要内容
临床试验/IRCT20230509058135N1
IRCT20230509058135N1招募中3 期

Investigating the effectiveness and side effects of Deep Lung Support capsule as adjuvant treatment with prefenidone compared to placebo on clinical symptoms, pulmonary function tests and serum TGF-ß levels in patients with idiopathic pulmonary fibrosis.

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
40 years 至 80 years(—)
性别
All

入选标准

  • Forced vital capacity (FVC) greater than 40% and less than or equal to 90%
  • Diffusing capacity of the lungs for carbon monoxide (DLCO) greater than or equal to 40% and less than or equal to 90%

排除标准

  • Having an FEV1/FVC ratio of less than 0.8 (after bronchodilator administration) at screening
  • Suffering from other interstitial lung diseases, history of asthma or chronic lung disease, active infection, being treated with other IPF treatment methods such as immunosuppressives and cytokine regulating agents.
  • History of unstable or worsening heart or lung disease (except IPF) in the past six months
  • Pregnant and lactating women

研究者

相似试验

The effect of deep lung support capsule in... | 临床试验